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Chagas disease is caused by the protozoan para-
site Trypanosoma cruzi, widespread in the Ameri-
can Continent. A recent report of the World Health
Organization estimated that 16-18 million people
are currently infected and that about 90 million
individuals living in endemic areas are at risk of
contracting T. cruzi infection. The high prevalence
and continental extension of Chagas disease in
Latin America, as well as the constant migration
of T. cruzi infected individuals to non-endemic ar-
eas, require efficient and practical diagnostic pro-
cedures (Schmunis 1991,Wendel & Gonzaga
1993).
Chagas disease is characterized by the chrono-
logical appearance of specific classes of antibod-
ies during the development of the infection. Anti-
bodies from IgM class first appears as a typical
sign of the acute phase of the disease, and there
are some reports of an increase of total and spe-
cific IgA antibody class at this early phase (Lorca
et al. 1995, Umezawa et al. 1996a). Antibodies of
the IgG class, already present in the acute phase,
accompanies the infection until the chronic phase.
Detection of antibodies against T. cruzi anti-
gens by serological methods is still the main sup-
port for diagnosis of Chagas disease. The commer-
cial available diagnostic tests are based on the
whole or semi-purified antigenic fractions from T.
cruzi epimastigote (the non-infective forms of the
parasite). Considerable variation in the reproduc-
ibility and reliability of these tests have been re-
ported by different laboratories, mainly to cross-
reactivity with other pathogens and standardiza-
tion of the reagents (Camargo et al. 1986). Diag-
nostic tests employing epimastigote antigenic ex-
tract have a limited specificity, associated to the
fact of they do not possess highly reactive epitopes
for IgG/IgM antibodies present in patients with
acute or congenital Chagas disease (Umezawa et
al. 1996a-c). The epimastigote antigenic fraction
is constituted by complex molecules, that favors
the appearance of false positive reactions and cross
reaction with sera from patients with another in-
fections, mainly visceral leishmaniasis (Chiller et
al. 1990). This antigenic heterogeneity does not
allow the differential diagnosis between the acute
and chronic phases, and also among the clinical
manifestations of Chagas disease.
EVALUATION OF RECOMBINANT ANTIGENS FOR
CHAGAS DISEASE SERODIAGNOSIS
As discussed above the commercial immuno-
diagnostic tests are based on the whole or semi-
purified extracts of T. cruzi. The lack of specific
and well characterized antigens prepared under
quality-control conditions have introduced a source
of variability in the final reagent and controversial
results have been obtained with these reagents
(Camargo et al. 1986). T. cruzi recombinant anti-
gens may provide a convenient tool to improve
current methods of serological diagnosis of Chagas
disease (Moncayo & Luquetti 1990, Levin et al.
1991, Krieger et al. 1992, Franco da Silveira 1992,
Paranhos et al. 1994, Pastini et al. 1994). Cloned
peptides carrying well defined epitopes can be pro-
duced on a large scale and with acceptable degree
of purity. For this reason, we have decided to evalu-
ate the diagnostic efficiencies of different T. cruzi
recombinant antigens in an ELISA format
(Umezawa et al. 1999). Six T. cruzi recombinant
antigens were expressed in fusion with glutathione
S-transferase (GST) in Escherichia coli and puri-
fied by affinity chromatography. The selected an-
tigens (H49, JL7, B13 and JL8, see Table) are com-
posed by tandem amino acid repeats and showed
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high sensitivity, specificity, and positive and nega-
tive predictive values in previous studies (Moncayo
& Luquetti 1990, Levin et al. 1991). Two non re-
petitive antigens A13 (Paranhos et al. 1990) and
1F8 (Gonzalez et al. 1985) were also included in
this evaluation. The diagnostic efficiency of the
ELISA using the six recombinant antigens was
carried out with 541 serum samples (304 samples
from chagasic patients, and 237 samples from
nonchagasic patients) from nine South and Cen-
tral America countries (Argentina, Brazil, Bolivia,
Chile, Colombia, El Salvador, Guatemala, Hondu-
ras and Venezuela). The development and evalua-
tion of the recombinant ELISA was carried out by
a central laboratory (E. Umezawa, Instituto de
Medicina Tropical da USP, SP, Brasil). The results
were compared to those obtained with the whole
extract of epimastigote forms.
Four recombinant antigens (1F8, H49, JL7 and
B13) showed high sensitivity varying from 93.4%
to 99%. A large number of individuals living in
endemic areas produce specific antibodies against
repetitive amino-acid antigens (H49, JL7 and B13).
Interestingly, the sensitivity (99%) and specificity
(99.6%) of 1F8 antigen is comparable to that other
repetitive antigens indicating that chronic chagasic
patients also display antibodies against non repeti-
tive antigens. Serum samples from chagasic pa-
tients reacted with, at least, one recombinant anti-
gen, suggesting that a mixture of recombinant an-
tigens may detect anti-T. cruzi antibodies in all of
serum samples used in this study. The positivity of
a hypothetical antigenic mixture composed by the
recombinant peptides H49 or JL7, B13 and 1F8
was calculated as being 100%. Available recombi-
nant antigens react with 87-99% of the chronic
chagasic sera, suggesting that the combination of
two or more antigens to build up a multi-antigen
immunoassay may result in a truly reliable T. cruzi
serodiagnostic test.
In this study the epimastigote antigen showed
100% of sensitivity. However, the specificity of
the epimastigote antigenic extract was lower (84%)
than recombinant proteins which displayed speci-
ficity values between 96.2% (JL8) to 99.6% (A13,
B13 and 1F8). The lower specificity of the
epimastigote antigen is mainly due to cross-react-
ing epitopes between T. cruzi and Leishmania sp.
Our results indicate that one of the major advan-
tage of recombinant ELISA for the serodiagnosis
of Chagas disease is the lack of cross-reaction with
other parasitic diseases such as leishmaniasis. As
it has been suggested by several authors (Levin et
al. 1991, Krieger et al. 1992, Pastini et al. 1994,
Umezawa et al. 1999), the use of a cocktail of re-
combinant antigens should provide a reliable T.
cruzi serodiagnostic test. Different complementary
antigens could be combined in a relatively simple
immunoassay, and lead to the development of a
multi-antigen diagnostic kit standardization for
routine diagnosis of Chagas disease.
DIFFERENTIAL DIAGNOSIS OF ACUTE, CONGENI-
TAL AND CHRONIC CHAGAS DISEASE BY WEST-
ERN BLOT WITH TRYPOMASTIGOTE EXCRETED/
SECRETED ANTIGENS (TESA-BLOT)
As it was discussed above, the diagnosis of
acute and congenital Chagas disease, and the fol-
low up of treated chagasic patients are of paramount
importance. So far, the unique test described to
control the parasitological cure of treated chagasic
patients is the lysis of bloodstream trypomastigotes
mediated by complement (Krettli et al. 1982). How-
ever, several groups point many methodological
difficulties for the inclusion of that test in the rou-
tine of clinical laboratories (Pereira et al. 1989).
For this reason, the search of specific antigens and/
or alternative tests remains important for the fol-
low up of the chagasic patients after drug treat-
ment (Almeida et al. 1991, Norris et al. 1994,
Krautz et al. 1994, Levy et al. 1996).
TABLE
Characteristics of Trypanosoma cruzi recombinant antigens used in this study
Antigen Repeat Size of No. of Size of the Function/cellular location References
(aa)a the insert  repeatsc fusion
(bp)b protein (kDa)
H49 68 978 4.5 63.5 Cytoskeleton associated protein Cotrim et al. 1990
JL7 68 747 3.6 58.0 Cytoskeleton associated protein Levin et al. 1989
B13 12 600 16.6 51.5 Cytoplasmic/surface antigen Gruber & Zingales 1993
JL8 14 351 6.7 42.1 Cytoplasmic antigen Levin et al. 1989
A13 none 755 none 56.0 Cytoplamic antigen Paranhos et al. 1990
1F8 none 600 none 51.5 Flagellar calcium binding protein Gonzalez et al. 1985
Godsel et al. 1995
a: number of amino acids (aa) in the repeat; b: size of the insert, in base pairs (bp), of the recombinant clone;
c: number of the repeats in the insert of the recombinant clone.
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We have developed an immunodiagnostic test
for Chagas disease using the TESA liberated, as
exoantigens, in the supernatant of mammalian cell
cultures infected with T. cruzi (Umezawa et al.
1996c). Exoantigens were collected from super-
natants of LLC-MK2 cell cultures, separated by
SDS-polyacrylamide gel electrophoresis and trans-
ferred onto nitrocellulose filters. The test was de-
veloped by immunoblotting and termed TESA-
blot. The main components of TESA antigens are
a 150-160-kDa protein and several components
(130-200 kDa) of SAPA antigen (Shed Acute Phase
Antigen), the last previously described by Frasch
and co-workers (Affranchino et al. 1989). The pres-
ence of SAPA/trans-sialidase in TESA-blot was
confirmed by reactivity with a specific antiserum
against SAPA as well as with IgG/IgM antibodies
from acute and congenital human sera (Umezawa
et al. 1996c).
The evaluation of TESA-blot was carried out
with serum samples from 512 patients, 111 non-
chagasic including cases of leishmaniasis and other
pathologies, and 401 chagasic patients includind
acute, congenital and chronic cases. TESA-blot
showed 100% of sensitivity and 100% of specific-
ity. Furthermore, this assay allows the discrimina-
tion between acute and chronic phases of Chagas
disease. We have found that IgGs from chronic
chagasic patients reacted with the 150-160 kDa
exoantigen whereas IgGs/IgMs from acute patients
reacted with the components of SAPA/trans-
sialidase. This test, until now, have been demon-
strated to be useful as a confirmatory test, since it
has been used to confirm several inconclusive re-
sults obtained by conventional serology. Prelimi-
nary results from our laboratory (Matsumoto &
Umezawa) showed that a 160 kDa antigen, ob-
tained from DNA recombinant technology, may
correspond to the CRP (Complement Regulatory
Protein), previously described by Norris et al.
(1994). Martins at al. (1985) had previously dem-
onstrated that reactivity with a 160-kDa
trypomastigote surface protein could discriminate
between cured treated patients from the non cured
ones. For these reasons, we started to use these
antigens in the follow up of chagasic patients sub-
mitted to chemotherapy.
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